Research programme: anti CD19 killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapies - Verismo Therapeutics
Alternative Names: KIR-CAR-19 - Verismo Therapeutics; KIR-CAR-CD19 - Verismo Therapeutics; SynKIR-19Latest Information Update: 15 Apr 2024
At a glance
- Originator Verismo Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 08 Apr 2024 Preclinical trials in Haematological malignancies in USA (Parenteral)
- 18 Oct 2021 Early research in Haematological malignancies in USA (Parenteral) as of October 2021 (Verismo Therapeutics pipeline; October 2021)
- 01 Apr 2021 HBL acquires manufacturing and marketing license from Verismo Therapeutics